Aclaris Therapeutics Shares Spike Higher; Piper Sandler Upgrads Stock To Overweight With $13 Target Following Biosion Deal; Highlights Pipeline For Atopic Dermatitis And I&I Market, Catalysts Expected In 2025 Trials
Aclaris Therapeutics Shares Spike Higher; Piper Sandler Upgrads Stock To Overweight With $13 Target Following Biosion Deal; Highlights Pipeline For Atopic Dermatitis And I&I Market, Catalysts Expected In 2025 Trials
aclaris therapeutics的股票大幅上漲；派傑投資將其評級上調至增持，目標價爲13美元，此舉是根據與Biosion的交易；強調了針對特應性皮炎和免疫炎症市場的產品管線，預計在2025年的試驗中會有催化劑跟進。
Aclaris Therapeutics Shares Spike Higher; Piper Sandler Upgrads Stock To Overweight With $13 Target Following Biosion Deal; Highlights Pipeline For Atopic Dermatitis And I&I Market, Catalysts Expected In 2025 Trials
aclaris therapeutics的股票大幅上漲；派傑投資將其評級上調至增持，目標價爲13美元，此舉是根據與Biosion的交易；強調了針對特應性皮炎和免疫炎症市場的產品管線，預計在2025年的試驗中會有催化劑跟進。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間